PA528X WISP3 antigen
see all 2 WISP3 products
20 µg / US$ 355
NOVUS BIOLOGICALS
PO Box 802 Littleton, CO 80160, USA
E-Mail: novus@novus-biologicals.com
Homepage: http://www.novus-biologicals.com
PO Box 802 Littleton, CO 80160, USA
E-Mail: novus@novus-biologicals.com
Homepage: http://www.novus-biologicals.com
Quick Overview
Human WISP3
Synonyms
CCN6, WISP-3, WNT1-inducible-signaling pathway protein 3,
Product Description
Human WISP3
Properties
| Species | Human |
| Purity | >98% |
| Source | E. coli |
| Molecular Weight | 36.8 kDa |
| Catalog Number | PA528X |
| Swiss Prot. No. | O95389 |
| Quantity | 20 µg |
| Price | US$ 355 |
| Delivery | Worldwide |
| Manufacturer | Acris Antibodies GmbH |
| Datasheet | view  PA528X.pdf |
Datasheet Extract
| Background | WISP-3 is a member of the CCN family of secreted cysteine rich regulatory proteins. It is predominantly expressed in the adult kidney, testis and fetal kidney and weaker expression in placenta, ovary, prostate, small intestine, and skeletally-derived cells. WISP-3 is required for normal postnatal skeletal growth and cartilage homeostasis. |
| Immunogen | Swiss Num.: O95389 |
| Source | E. coli |
| Format | State: Lyophilized purified fraction (>98% pure by SDS-PAGE gel and HPLC analyses). Endotoxinlevel: < 0.1 ng/µg (1 EU/µg) Reconstitution: Restore in water to a concentration of 0.1-1.0 mg/ml. |
| Description | Human WISP-3 is a 36.8 kDa protein containing 331 amino acid residues.
It is composed of four distinct structural domains (modules); the IGF binding protein (IGFBP) domain, the von Willebrand Factor C (VWFC) domain, the thrombospondin type-1 repeat (TSP type-1) domain, and a C-terminal cystine knot-like (CTCK) domain. AASequence: TGPLDTTPEG RPGEVSDAPQ RKQFCHWPCK CPQQKPRCPP GVSLVRDGCG CCKICAKQPG EICNEADLCD PHKGLYCDYS VDRPRYETGV CAYLVAVGCE FNQVHYHNGQ VFQPNPLFSC LCVSGAIGCT PLFIPKLAGS HCSGAKGGKK SDQSNCSLEP LLQQLSTSYK TMPAYRNLPL IWKKKCLVQA TKWTPCSRTC GMGISNRVTN ENSNCEMRKE KRLCYIQPCD SNILKTIKIP KGKTCQPTFQ LSKAEKFVFS GCSSTQSYKP TFCGICLDKR CCIPNKSKMI TIQFDCPNEG SFKWKMLWIT SCVCQRNCRE PGDIFSELKI L Biological Activity: The ED50 was determined by the dose-dependant proliferation of the MCF-7 cell line. The expected ED50 for this effect is 0.2-0.3 µg/ml. |
| Storage | Store the lyophilized antigen at 2-8°C for one month or (in aliquots) at -20°C for longer.
Store reconstituted protein in aliquots at -20°C. Avoid multiple freeze/thaw cycles. Shelf life: six months from despatch. |
| References | 1.Kleer CG, Zhang Y, Merajver SD, CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer. Cells Tissues Organs. 2007;185(1-3):95-9. Review.
2.Parisi MS, Gazzerro E, Rydziel S, Canalis E. Expression and regulation of CCN genes in murine osteoblasts. Bone. 2006, 38(5):671-7. 3. Schutze N, Noth U, Schneidereit J, Hendrich C, Jakob F. Differential expression of CCN-family members in primary human bone marrow-derived mesenchymal stem cells during osteogenic, chondrogenic and adipogenic differentiation. Cell Commun Signal. 2005, 3(1):5. 4. Zhou HD, Peng YQ, Gu W, Li J, Xie H, Liu M, Luo XH, Huang QX, Guo LJ, Yuan LQ, Ni JD, Zhang XS, Liao EY.[Characterization of biologic behaviors and cDNA expression of articular chondrocytes in spondyloepiphyseal dysplasia tarda with progressive arthropathy] Zhonghua Nei Ke Za Zhi. 2005, 44(1):16-21. Chinese. 5. Peng YQ, Liao EY, Gu HM, Wei QY, Zhou HD, Li J, Xie H, Zhai MX, Tan LH, Luo XH, Wu XP, Hu PA, Ni JD, Su X, Jiang Y, Dai RC, Guo LJ, Yuan LQ, Wang M, Wang PF, Liu SP, Yang Y, Wang C, Sui GL, Fang TY.[Pathology and molecular pathogenesis of spondyloepiphyseal dysplasia tarda with progressive arthropathy caused by compound CCN6 heterogeneous gene mutations]Zhonghua Yi Xue Za Zhi. 2004,84(21):1796-803. Chinese. 6. Lin CG, Chen CC, Leu SJ, Grzeszkiewicz TM, Lau LF.Integrin-dependent functions of the angiogenic inducer NOV (CCN3): implication in wound healing. J Biol Chem. 2005, 280(9):8229-37. 7. Desnoyers L.Structural basis and therapeutic implication of the interaction of CCN proteins with glycoconjugates. Curr Pharm Des., 2004, 10(31):3913-28. Review. 8. Huang CL, Liu D, Masuya D, Kameyama K, Nakashima T, Yokomise H, Ueno M, Miyake M.MRP-1/CD9 gene transduction downregulates Wnt signal pathways. Oncogene. 2004, 23(45):7475-83. |
